Surgical Management and Outcomes in Patients with Cushing Disease with Negative Pituitary Magnetic Resonance Imaging

详细信息	查看全文 | 推荐本文 |

• 作者：Shozo Yamada¹ ; ⁵ ; ^{syamadays11@hotmail.com} ; Noriaki Fukuhara¹ ; Hiroshi Nishioka¹ ; ⁵ ; Akira Takeshita² ; ⁵ ; Naoko Inoshita³ ; Junko Ito⁴ ; ⁵ ; Yasuhiro Takeuchi² ; ⁵
• 关键词：Cushing disease ; Long-term outcome ; Microadenoma ; Normal magnetic resonance imaging ; Transsphenoidal surgery
• 刊名：World Neurosurgery
• 出版年：2012
• 期刊代码：pca372_18788750
• 类别：med
• 出版时间：March-April, 2012
• 卷：77
• 期：3-4
• 页码：525-532
• 文件大小：1108 K

摘要

| Figures/TablesFigures/Tables | ReferencesReferences

Objective

To analyze our experience with transsphenoidal surgery (TSS) in patients with Cushing disease (CD) with no visible adenoma on magnetic resonance imaging (MRI).

Methods

Between January 1988 and October 2010, 183 patients with CD underwent TSS at Toranomon Hospital. We retrospectively analyzed data in 18 patients without visible adenomas on MRI and compared them with 106 patients with microadenomas.

Results

Of 106 patients with MRI-visible microadenomas, postoperative remission was achieved in 104 patients (98.1%) and recurrence of CD was observed in 4 patients (3.8%) during a mean follow-up of 5.2 years. Of the 18 patients with negative MRI, postoperative remission was achieved in 0 of the 3 patients with negative inferior petrosal sinus sampling (IPSS), in 50%of those with positive IPSS (7 of 14 patients), and in 1 patient with inconclusive IPSS. No disease recurrence has been observed during a mean follow-up of 3.3 years in the 8 patients with remission, and no tumor has emerged on MRI in 10 patients with failed surgery during a mean follow-up of 4.2 years. No major perioperative complications, including hypopituitarism, occurred in this series.

Conclusions

When the pituitary origin of adrenocorticotropic hormone secretion is established by IPSS in patients with normal MRI findings, we recommend TSS as the first-line treatment for CD, although chance of surgical cure (50%in this series) is lower than that of MRI-visible microadenomas. In contrast, other therapeutic options must be considered in patients with negative MRI and IPSS findings.